瑞芬太尼与丙泊酚复合在门诊无痛胃镜中的应用

目的观察瑞芬太尼复合丙泊酚在门诊无痛胃镜中的应用效果。方法 60例门诊无痛胃镜检查患者随机分为瑞芬太尼与丙泊酚复合组(A)和芬太尼与丙泊酚复合组(B)各30例。两组静注异丙酚1.5-2.0mg/kg后,A组静注瑞芬太尼0.5ug/kg,B组静注芬太尼0.05mg。术中根据患者情况适当追加异丙酚,观察SpO2、HR、SBP的变化,病人的异丙酚用量、检查时间、苏醒时间、可行走时间。结果苏醒时间和可行走时间A组显著短于B组,两组比较差异有统计学意义(P<0.05)。异丙酚的用量B组稍高于A组,但两组比较差异无统计学意义(P>0.05)。结论瑞芬太尼复合异丙酚用于无痛胃镜检查具有苏醒快,可行走时间短,镇痛效果满意等优点,而且安全。     

瑞芬太尼复合异丙酚与芬太尼复合异丙酚用于无痛人流的比较分析

目的 :比较瑞芬太尼复合异丙酚与芬太尼复合异丙酚用于无痛人流的临床效果。方法 :1 0 0例要求终止妊娠的早孕妇女随机分成芬太尼组 (A组 ,5 0例 )和瑞芬太尼组 (B组 ,5 0例 ) ,两组均先分别静注芬太尼、瑞芬太尼后静注异丙酚 1 .5mg/kg诱导 ,A组静注芬太尼 0 .0 5mg ,B组静注瑞芬太尼 0 .0 5mg ,术中静脉追加异丙酚 0 .5mg/kg ,观察SpO2 、HR、MAP变化、异丙酚总用量、镇痛效果。结果 :术中异丙酚追加量和总用药量A组显著高于B组 (P <0 .0 5 ) ,苏醒时间A组显著长于B组。呼吸循环的变化两组间无显著差异。结论 :瑞芬太尼较芬太尼用于无痛人流具有药效、安全相似 ,但镇痛强 ,苏醒较快、镇痛效果满意等优点 ,值得推广应用。     

瑞芬太尼复合异丙酚静脉麻醉在125Ⅰ粒子植入或射频消融术中的麻醉效果观察

目的:将瑞芬太尼复合异丙酚应用于治疗经皮射频消融或125Ⅰ粒子植入治疗恶性肿瘤的麻醉.探讨其临床效果以及安全性.方法:选择射频治疗或125Ⅰ粒子植入患者60例,随机分为瑞芬太尼复合异丙酚组(A组)与芬太尼复合异丙酚组(B组),每组各30例.A组用微量泵输注瑞芬太尼0.1μg/(kg·min),B组静注芬太尼1.5μg/kg,两组均以异丙酚微量泵维持麻醉.监护仪记录术前、手术开始时、手术开始后5min及患者术后苏醒时的平均动脉压、心率、脉搏氧饱和度及呼吸频率,记录患者苏醒时间;记录术中体动、呼吸暂停次数.结果:瑞芬太尼组患者的清醒时间显著短于芬太尼组,异丙酚用量瑞芬太尼组显著少于芬太尼组(P<0.001).术中瑞芬太尼组的平均动脉压下降明显低于芬太尼组(P<0.05).结论:经皮射频消融或125Ⅰ粒子植入治疗恶性肿瘤的麻醉术中应用微量泵静脉输注瑞芬太尼复合异丙酚麻醉效果确切、安全,但需要加强呼吸循环监护与管理.     

丙泊酚复合芬太尼瑞芬太尼用于无痛人流术

目的:观察丙泊酚复合瑞芬太尼麻醉用于门诊无痛人流术的临床效果和安全性。方法:选择120例早孕需人工流产者随机分为三组。A组:丙泊酚2.5mg/kg。B组:丙泊酚1.5mg/kg+芬太尼2μg/kg。C组:丙泊酚1.5mg/kg+瑞芬太尼2μg/kg。观察术前、术中、术后的MAP、HR、sPO2、麻醉效果、丙泊酚的用量、手术时间、睁眼时间、定向力恢复时间、离院时间及并发症。结果:丙泊酚的用量、睁眼时间、定向力恢复时间、离院时间A组明显高于B、C两组,C组用量最少、苏醒时间最短。结论:丙泊酚复合芬太尼和瑞芬太尼用于无痛人流术效果好,丙泊酚用量明显减少,苏醒时间明显缩短,而以丙泊酚复合瑞芬太尼的效果最好。     

瑞芬太尼复合异丙酚用于无痛人工流产麻醉临床观察

目的临床观察瑞芬太尼复合异丙酚用于无痛人流的效果及安全性。方法60例早期妊娠孕妇随机分为两组,每组30例。异丙酚组（D组）：异丙酚2.5 mg/kg,缓慢静注。异丙酚加瑞芬太尼组（R组）。静注瑞芬太尼1.0μg/kg,异丙酚1.0 mg/kg,再静脉泵入瑞芬太尼0.1μg/（kg.min）-1。必要时追加0.5 mg/kg。结果两组病人均顺利完成手术,R组苏醒时间明显短于D组,体动反应、术中SpO2下降、低血压的发生少于D组,两组比较差异有显著性（P〈0.05）。瑞芬太尼与异丙酚配伍用于无痛人流的麻醉是一种理想的麻醉方法,能达到满意的麻醉效果。     

瑞芬太尼与芬太尼复合异丙酚麻醉用于胃镜检查术的临床观察

目的：比较三种不同静脉麻醉方法行胃镜检查术的麻醉效果。方法：将择期行胃镜检查术患者120例,随机分为异丙酚组（P组）、芬太尼复合异丙酚组（F组）、瑞芬太尼复合异丙酚组（R组）,每组40例。P组单纯静注异丙酚2．5mg／kg;F组先后静注芬太尼1.0μg／kg、异丙酚LSmg／kg;R组先后静注瑞芬太尼0．5Dg／kg、异丙酚1．5mg／kg。患者入睡后开始手术。术中如有影响手术操作的体动和呛咳,追加异丙酚0．5mg／kg。结果：与P组比较,F组和R组麻醉效果满意,异丙酚用量明显减少（P〈0．05）,术毕清醒及离院时间更短（P〈0．05）。结论：芬太尼及瑞芬太尼复合异丙酚均可有效而安全的用于胃镜检查术。     

浅谈丙泊酚复合瑞芬太尼静脉麻醉在无痛胃镜检查中的应用分析

目的探讨分析丙泊酚复合瑞芬太尼静脉麻醉在无痛胃镜检查中安全性和可行性。方法将ASA分级Ⅰ~Ⅱ级行胃镜检查的患者200例,随机分为2组:X组100例,丙泊酚复合瑞芬太尼麻醉,静脉注射丙泊酚1.0 mg/kg及瑞芬太尼0.5μg/kg;Y组100例,丙泊酚复合芬太尼麻醉,静脉注射丙泊酚1.0 mg/kg及芬太尼0.5μg/kg,比较两组患者的苏醒时间、离院时间以及丙泊酚的用量。结果 X组丙泊酚的用量少于Y组(P0.05),X组的苏醒时间短于Y组(P0.05),X组的离院时间早于Y组(P0.05)。结论丙泊酚复合瑞芬太尼静脉麻醉在无痛胃镜检查中能够明显的减轻患者检查所造成的痛苦和不良反应,是一种安全、苏醒时间短、离院时间早的麻醉方法,并可减少丙泊酚的用量,值得临床推广使用。     

靶控输注瑞芬太尼复合异丙酚在无痛人工流产中的应用

①目的探讨靶控输注瑞芬太尼复合异丙酚在无痛人工流产中应用的可行性及其效果。②方法选择需行人工流产的早孕患者150例，随机分为3组。A组为瑞芬太尼复合异丙酚组，B组为芬太尼复合异丙酚组，C组为异丙酚组。A组瑞芬太尼以TCI泵设定血泉靶浓度1ng／mL给药并维持；B组芬太尼予1μg／mL单次静注，两组随后静注异丙酚0．5mg／kg；C组：异丙酚予2mg／kg持续静注60秒。观察并记录各组诱导时间、手术时间、苏醒时间、离院时间、异丙酚总用量、术申监护数值（包括SBP，DBP，HR，SPO2，BIS）以及恶心呕吐、呼吸抑制等不良反应和VAS评分。③结果A组诱导时间、苏醒时间、离院时间最短，与B、C组比较有显著性差异（P〈0．01）；异丙酚用量仅（60．2±18．4）mg，3组中用量最少，与B、C组比较同样有显著性差异（P〈0．01）。手术中各组监测值均有一定的下降，与诱导前比有显著性差异（P〈0．01或P〈0．05），其中以C组下降幅度最大。BIS值，A组为65．4±12．5较B、C组维持在较高的水平，处于麻醉较践的状态中。VAS评分，A和B分别为9．9±0．2、9．5±1．3，较C组有显著性差异（P〈0．01）。④结论靶控输注瑞芬太尼复合异丙酚。术中循环稳定，苏醒迅速，镇痛效果确切。     

瑞芬太尼复合异丙酚静脉麻醉在^125I粒子植入或射频消融术中的麻醉效果观察

目的：将瑞芬太尼复合异丙酚应用于治疗经皮射频消融或^125I粒子植入治疗恶性肿瘤的麻醉。探讨其临床效果以及安全性。方法：选择射频治疗或^125I粒子植入患者60例,随机分为瑞芬太尼复合异丙酚组（A组）与芬太尼复合异丙酚组（B组）,每组各30例。A组用微量泵输注瑞芬太尼0.1μg/（kg·min）,B组静注芬太尼1.5μg/kg,两组均以异丙酚微量泵维持麻醉。监护仪记录术前、手术开始时、手术开始后5min及患者术后苏醒时的平均动脉压、心率、脉搏氧饱和度及呼吸频率,记录患者苏醒时间;记录术中体动、呼吸暂停次数。结果：瑞芬太尼组患者的清醒时间显著短于芬太尼组,异丙酚用量瑞芬太尼组显著少于芬太尼组（P〈0.001）。术中瑞芬太尼组的平均动脉压下降明显低于芬太尼组（P〈0.05）。结论：经皮射频消融或^125I粒子植入治疗恶性肿瘤的麻醉术中应用微量泵静脉输注瑞芬太尼复合异丙酚麻醉效果确切、安全,但需要加强呼吸循环监护与管理。     

丙泊酚复合舒芬太尼用于无痛人流术效果观察

目的:比较丙泊酚复合小剂量舒芬太尼或芬太尼对无痛人流术的临床方法、效果及安全性.方法:选择150例择期行无痛人流术患者,随机分为A、B组,A组缓慢静注0.1μg/kg舒芬太尼,3min后缓慢静注丙泊酚1.5～2mg/kg,B组缓慢静注1μg/kg芬太尼,3min后缓慢静注丙泊酚1.5 ～ 2mg/kg,观察不同时间点的呼吸、循环变化及不良反应,记录入睡时间、苏醒时间、麻醉药用量.结果:患者呼吸循环稳定,各时间点血压、心率、呼吸比较两组无显著性差异.恶心呕吐发生情况两组无显著性差异.A组入睡时间、苏醒时间均短于B组(P＜0.05);丙泊酚用量较B组减少(P＜0.05),术中体动、术后宫缩痛发生率较B组更低(P＜0.05).结论:丙泊酚复合小剂量舒芬太尼,用于无痛人流术效果优且不良反应少,术后清醒快,患者满意率高,麻醉更安全.     

Value of D-Dimers in patients with acute aortic dissection

Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P ＜ 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (＞0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P ＜0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P ＜ 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.     

Research of combined liver-kidney transplantation model in rats

Objective： To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods： SD rats served as both donors and recipients. 4℃ sodium lactate Ringer＇s was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava （IVC） inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results： Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion： This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

安心颗粒对急诊经皮冠状动脉介入术后生活质量影响的研究

目的：评价使用安心颗粒对急诊经皮冠状动脉介入术（PPCI）术后生活质量的影响.方法：将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组（术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次）和对照组（仅接受基础药物治疗）.所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表（MIDAS）、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果：入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异（P＞0.05）;出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低（P＜0.05）;组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低（P＜0.05）.两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血（P＞0.05）.两组发生轻度血小板减少症的患者数比较无差异（P＞0.05）.结论：PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.     

The comparative studies of the influences of Urapidil and Nicardipine on sino-atrial node function, atrio-ventricular node function and hemodynamics

Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P＜0.01);the MAP decreased(P＜0.01)and the HR increased drastically(P＜0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.     

Expression of OPGmRNA and ODFmRNA in the patients of hip fracture due to osteoporosis

Objective：To investigate the gene expression of osteoprotegerin（OPG） and osteoclast differentiation factor（ODF） in the bone tissue of patients with hip fracture due to osteoporosis. Methods：OPGmRNA and ODFmRNA in the bone tissue in 50 cases of osteoporosis sufferers（over 50 years old） with hip fracture（Observer Group） and 30 cases of hip facture sufferers with no osteoporosis（Control group） were analyzed with the Semi-Quantitative RT-PCR method. Results：The mRNA expressed of ODF, OPG were both high in the patients with hip fracture. In the control group, the expression of OPG mRNA was observed, while the expression of ODF mRNA was very slight. Conclusion：Aged patients contained all signals including OPG, ODF that are essential for inducing osteoclastogenesis and promoting bone resorption.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

Luo Lingjie's Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Dr.Zhang Ren's Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

The clinicopathological and immuohistochemical analysis of solid-pseudopapillary tumor of the pancreas： report of 9 cases

Objective：To investigate the clinical features, pathological characteristics and immunophenotype of solid-pseudopapillary tumor of the pancreas（SPTP）. Methods：Nine surgically treated cases of SPTP were retrospectively reviewed. Hematoxylin and Eosin（HE） staining and immunohistochemical staining were used to analyze all cases, and the general clinical data was collected. Results：Six patients were asymptomatic except for a palpable mass. Two patients complained of vague-epigastric pain. One patient appeared jaundice. The tumor was encapsulated and solid tissues alternately with cystic tissues. Histologically, the histological structure of solid portion was pseudopapillary with a fibrovascular core. Tumor cells were uniform and medium-sized which were arranged in sheets ets or nests or pseudopapillary patterns. Immunohistochemical studies demonstrated that SPTP proved positive in vimentin（9/9 cases）, AAT（9/9 cases）, NSE（9/9 cases）, ACT（7/9 cases）, CK20（2/9 cases）, CgA（1/9 cases）, S-100（3/gcases）, PR（4/gcases）, Syn（3/9 cases） and CD56（5/9cases）, negative in CEA and ER. Conclusion：SPTP is a tumor predominantly occurring in young women frequently without special symptoms. This tumor has various characteristical histological patterns with different immunophenotype.